ONNVF.US Onco-Innovations Limited
- Market cap
- USD 9.87M
- P/E
- -
- P/B
- 4.97x
- ROE
- -472.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is ONNVF.US undervalued?
Graham numberThe Graham number of Onco-Innovations Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Onco-Innovations Limited fundamental analysis
No fundamental analysis for Onco-Innovations Limited yet.
Onco-Innovations Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Onco-Innovations Limited
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company's lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. …
Full company profileOnco-Innovations Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Onco-Innovations Limited annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 65.3K | 110K | 0.00 |
| Operating Income | -234.00 | -266K | -4.66M | -10.8M | -9.22M |
| EBITDA | -234.00 | -266K | -4.66M | -10.8M | -13.4M |
| Net Income | -234.00 | -421K | -7.56M | -10.8M | -13.4M |
| EPS | 0.00 | -0.01 | -0.15 | -0.18 | -0.20 |
| Balance Sheet | |||||
| Total Assets | 18.5K | 556K | 2.22M | 1.24M | 4.53M |
| Total Liabilities | 0.00 | 193K | 410K | 853K | 1.69M |
| Shareholders' Equity | 18.5K | 363K | 1.81M | 390K | 2.83M |
| Cash & Short-term Investments | 18.5K | 500K | 1.11M | 776K | 114K |
| Cash Flow | |||||
| Operating Cash Flow | -233.00 | -6.30K | -3.87M | -5.27M | -3.07M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -233.00 | -6.30K | -3.87M | -5.27M | -3.07M |
| Ratios | |||||
| ROE | -1.3% | -115.9% | -418.8% | -2,763.4% | -472.7% |
| ROA | -1.3% | -75.7% | -341.4% | -866.8% | -295.9% |
| Net Profit Margin | - | - | -11,580.6% | -9,763.4% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Onco-Innovations Limited dividends
Onco-Innovations Limited has not paid dividends in the last 4 fiscal years.
Who owns Onco-Innovations Limited
- Insiders 1.05%
- Institutions 0.00%
- Public & others 98.95%
- Shares outstanding 69.2M
- Free float 66.7M
Onco-Innovations Limited company profile
- Company name
- Onco-Innovations Limited
- Ticker
- ONNVF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- April
- Address
- 1122 ? 4th Street SW, Calgary, AB, Canada, T2R 1M1
- Phone
- 848-488-9277
- Website
- oncoinnovations.com
About Onco-Innovations Limited
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company's lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities. It has collaborations with Dalton Pharma Services, the University of Alberta and Cross Cancer Institute, Nucro-Technics Inc., and Avance Clinical Pty Ltd. Onco-Innovations Limited is headquartered in Calgary, Canada.
Onco-Innovations Limited management
6- Mr. Thomas O'ShaughnessyChief Executive Officer · born 1977
- Mr. David M. Antony C.A.CFO & Corporate Secretary · born 1963
- Mr. Stephen M. NovakChief of Research & Development
- Dr. Islam Mohamed B.Sc., FRCPC, M.D.Chairman of Scientific, Chief Medical Officer & Clinical Advisory Board
- Dr. Fadia Saad M.B.A., Ph.D.Consultant · born 1964
- Dr. Frederick WestTechnology Transfer Advisor